Optimal concentration of tacalcitol in once-daily treatment of psoriasis

References

• Baadsgaard O, Fisher G, Voorhees J J., et al. The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990; 95: 32S–34S
   Web of Science ®Google Scholar
• Baadsgaard O, Gupta A K., Taylor R S., et al. Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells. J Invest Dermatol 1989; 92: 190–5
   PubMed Web of Science ®Google Scholar
• Baadsgaard O, Tong P, Elder J T., et al. UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol 1990; 95: 275–82
   PubMed Web of Science ®Google Scholar
• Strange P, Cooper K D., Hansen E R., et al. Lesional psoriatic T-lymphocytes release lymphokines that induce keratinocyte proliferation. J Invest Dermatol 1993; 101: 695–700
   PubMedGoogle Scholar
• Kragballe K, Wildfang I L. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990; 282: 164–7
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Hashimoto K, Kiyoki M, et al. Effect of 1,24(R)-dihydroxyvitamin D3 on the growth of human keratinocytes. J Dermatol 1990; 17: 97–103
   PubMedGoogle Scholar
• Matsunaga T, Yamamoto M, Mimura H, et al. 1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J Dermatol 1990; 17: 135–42
   PubMedGoogle Scholar
• Rigby W F., Noelle R J., Krause K, et al. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J Immunol 1985; 135: 2279–86
   PubMed Web of Science ®Google Scholar
• Rigby W F., Stacy T, Fanger M W. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 1984; 74: 1451–5
   PubMed Web of Science ®Google Scholar
• Kim H J., Abdelkader N, Katz M, et al. 1,25-dihydroxyvitamin D3 enhances antiproliferative effect and transcription of TGF-β1 on human keratinocytes in culture. J Cell Physiol 1992; 151: 579–87
   PubMedGoogle Scholar
• Baker A R., McDonnell D P., Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85: 3294–8
   PubMed Web of Science ®Google Scholar
• Clemens T L., Garrett K P., Zhou X Y., et al. Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology 1988; 122: 1224–30
   PubMedGoogle Scholar
• Jordan S C., Toyoda M, Prehn J, et al. 1,25-dihydroxyvitamin-D3 regulation of interleukin-2 and interleukin-2 receptor levels and gene expression in human T cells. Mol Immunol 1989; 26: 979–84
   PubMedGoogle Scholar
• Müller K, ødum N, Bendtzen K. 1,25-dihydroxyvitamin D3 selectively reduces interleukin-2 levels and proliferation of human T cell lines in vitro. Immunol Lett 1993; 35: 177–82
   PubMed Web of Science ®Google Scholar
• Reichel H, Koeffler H P., Tobler A, et al. 1α,25-dihydroxyvitamin D3 inhibits γ-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1987; 84: 3385–9
   PubMed Web of Science ®Google Scholar
• Rigby W F., Hamilton B J., Waugh M G. 1,25-dihydroxyvitamin D3 modulates the effects of interleukin 2 independent of IL-2 receptor binding. Cell Immunol 1990; 125: 396–414
   PubMed Web of Science ®Google Scholar
• Müller K, Haarh P M., Diamant M, et al. 1,25-dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the posttranscriptional level. Cytokine 1992; 4: 506–12
   PubMed Web of Science ®Google Scholar
• Lemire J M., Archer D C. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991; 87: 1103–7
   PubMed Web of Science ®Google Scholar
• Lemire J M., Ince A, Takashima M. 1,25-dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/I mice. Autoimmunity 1992; 12: 143–8
   PubMed Web of Science ®Google Scholar
• Mathieu C, Laureys J, Sobis H, et al. 1,25-dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 1992; 41: 1491–5
   PubMed Web of Science ®Google Scholar
• Morimoto S, Onishi T, Imanaka S, et al. Topical administration of 1,25-dihydroxyvitamin D3 for psoriasis: report of five cases. Calcif Tissue Int 1986; 38: 119–22
   PubMedGoogle Scholar
• Morimoto S, Yoshikawa K, Kozuka T, et al. Treatment of psoriasis vulgaris by oral administration of 1α-hydroxyvitamin D3-open-design study. Calcif Tissue Int 1986; 39: 209–12
   PubMed Web of Science ®Google Scholar
• Morimoto S, Yoshikawa K, Kozuka T, et al. Treatment of psoriasis vulgaris with oral 1α,25-dihydroxyvitamin D3-report of two cases. J Dermatol 1987; 14: 59–62
   PubMedGoogle Scholar
• Morimoto S, Yoshikawa K, Kozuka T, et al. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 1986; 115: 421–9
   PubMed Web of Science ®Google Scholar
• Staberg B, Roed-Petersen J, Menné T. Efficacy of topical treatment in psoriasis with MC 903 a new vitamin D analogue. Acta Derm Venereol (Stockh) 1989; 69: 147–50
   PubMed Web of Science ®Google Scholar
• Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 1989; 125: 1647–52
   PubMedGoogle Scholar
• Kato T, Rokugo M, Terui T, et al. Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1α,24-dihydroxycholecalciferol. Br J Dermatol 1986; 115: 431–3
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Goto M, Ohkawara A, et al. Study for setting optimal concentration of TV-02 ointment. Nishinihon J Dermatol 1989; 51: 310–16
   Google Scholar
• Eto M, Nishiyama S, Nakamizo Y, et al. Safety confirmation study on TV-02 ointment to patients with psoriasis. Nishinihon J Dermatol 1989; 51: 317–24
   Google Scholar